IFITM3 at the viral fusion-pore checkpoint: membrane energetics and entry-route-dependent outcomes. [PDF]
Mao L +8 more
europepmc +1 more source
Influenza A and other respiratory viruses show distinct associations with acute respiratory presentations and temporal correlation with hospital admissions. [PDF]
Husein M +5 more
europepmc +1 more source
Related searches:
Characterization of particulate impurities such as aggregates is necessary to develop safe and efficacious adeno-associated virus (AAV) drug products. Although aggregation of AAVs can reduce the bioavailability of the virus, only a limited number of studies focus on the analysis of aggregates.
Cornelia Hiemenz +8 more
openaire +2 more sources
AbstractBackground and ObjectiveHypoglycemia induced by direct‐acting antiviral agents (DAAs) for chronic hepatitis C virus (HCV) infection is a rare but potentially life‐threatening adverse reaction, which led to warnings by competent authorities. We therefore aimed to examine the hypoglycemic safety signal for DAAs.MethodsReports to the US Food and ...
Yu, Zhou +5 more
openaire +2 more sources
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018
Drug Resistance Updates, 2018Nowadays, due to the development of potent Direct-Acting Antiviral Agents (DAAs) that specifically target NS3, NS5A and NS5B viral proteins, several new and highly efficacious options to treat chronic Hepatitis C virus (HCV) infection are available. The natural presence of resistance associated substitutions (RASs), as well as their rapid emergence ...
Sorbo M. C. +6 more
openaire +3 more sources
AimsDevelopment of direct‐acting antivirals (DAAs) has made antihepatitis C virus (HCV) treatment highly safe and effective. However, the emergence of resistant‐associated variants (RAVs) after failure of DAA therapy affects retreatment outcomes. In particular, genotype 1 HCV with P32 deletion has been reported to be highly resistant to all approved ...
Goki Suda +14 more
openaire +2 more sources
Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b HCV with drug resistance-associated variants in prior DAA treatment failures and human hepatocyte transplanted mice 1.Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures 2.Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice [PDF]
内容の要旨 ...
openaire +1 more source
Cervical cancer prevention and control in women living with human immunodeficiency virus
Ca-A Cancer Journal for Clinicians, 2021Vikrant V Sahasrabuddhe +2 more
exaly

